We tested the effectiveness and safety of i.v. diltiazem in the management of paroxysmal supraventricular tachyarrhythmias in 39 patients, 21 with organic heart disease and seven in heart failure.
ALTHOUGH digitalis has traditionally been used for the management of supraventricular tachyarrhythmias, one cannot rely on it to restore sinus rhythm promptly. Verapamil has had a major impact on the therapy of supraventricular tachyarrhythmias.2 Prolongation of atrioventricular (AV) nodal refractoriness and slowing of conduction provide the electrophysiologic basis for its antiarrhythmic action.'0 Verapamil, however, manifests negative inotropic properties .4 Profound hypotension and cardiac arrest have been observed in isolated cases after its administration to patients who were in congestive heart failure or who were receiving /8 blockers.3 2 16Thus, the availability of an antiarrhythmic drug with fewer severe side effects but with equal therapeutic efficacy is needed.
Diltiazem is a slow-channel calcium blocker with no discernible negative inotropic action'7-21 that shares some of the electrophysiologic properties of verapa-mil22. 23 However, the antiarrhythmic potental of diltiazem in the clinical management of patients with paroxysmal supraventricular tachyarrhythmias has not been tested. The aim of the present study was to assess the safety and therapeutic effectiveness of i.v. diltiazem in patients who presented with a paroxysmal supraventricular tachyarrhythmia. The drug was administered as an i.v. bolus over 2 minutes to achieve specific antiarrhythmic end points.
Methods

Patients
Thirty-nine patients, 13 men and 26 women, were studied. Their mean age was 56 years (range years). A paroxysmal supraventricular tachyarrhythmia was defined as one that started within 48 hours before treatment and was sustained. The diagnosis was supraventricular tachycardia (regular tachycardia with narrow QRS in a 12-lead ECG) in 15 patients, atrial flutter in 12 and atrial fibrillation in 12 patients. Twenty-one patients had underlying organic heart disease, three of whom showed signs of congestive heart failure on admission (patients 13, 15 and 30) . Four patients presented with left heart failure (New York Heart Association class II in patients 7 and 36 and class III in patients 16 and 39). The tachyarrhythmia was considered the cause of heart failure in patients 7, 16 and 36. At the time that diltiazem was administered, three patients were receiving long-term quinidine therapy, eight had received digoxin treatment and one patient was receiving digoxin and propranolol.
Study Design
The protocol was approved by the institutional human research committee. A description of the medication and the possible side effects were explained. Each patient gave written informed consent. Carotid sinus massage was attempted and was unsuccessful in all patients before they were considered for entry into the study. Previous treatment with antiarrhythmic or ,3blocking drugs was not a contraindication to entry into the study. Clinical end points that determined a successful result after administration of diltiazem were conversion to sinus rhythm or a slowing of the ventricular rate to 100 beats/min or less.
The first 33 patients were given a bolus injection of 150 Ag/kg, with a second injection scheduled for pa-tients who failed to achieve the end point within 30 minutes. Thirteen patients required repeat diltiazem administration; three received a second injection of 150 ug/kg and 10 were given a dose of 300 ug/kg. The last six patients received a single bolus injection of 300 ,uglkg. In each patient, diltiazem was infused through an antecubital vein over a period of 2 minutes. Intracardiac electrophysiologic studies were not performed.
The ECG was monitored before, during and for 30 minutes after the last i.v. dose of diltiazem. Selected tracings were recorded on a strip-chart recorder at a paper speed of 25 mm/sec. Heart rate was determined over a 1-minute period at 5-minute intervals. Cuff blood pressure was measured each minute for the first 5 minutes after diltiazem administration and at 5-minute intervals for 30 minutes. Calcium chloride was available for use with each injection of diltiazem. All patients were kept in the hospital at least 4 hours and questioned carefully with regard to symptoms and side effects.
Data Analysis
Differences in heart rate and blood pressure measured before and after diltiazem administration were analyzed for significance using a t test. A p value of 0.05 or less was considered statistically significant.
Results
Paroxysmal Supraventricular Tachycardia
Carotid sinus massage, performed before the administration of i.v. diltiazem, failed to convert the tachycardia. Diltiazem converted 13 of the 15 patients (87%) to sinus rhythm (table 1). Sinus activity promptly returned to normal with effective doses of diltiazem: 11 of the 13 patients reverted to sinus rhythm within 5 minutes, nine of them within 2 minutes. Four patients had one or more ventricular extrasystoles at the time of conversion. Preexcitation was never observed after termination of tachycardia. One patient showed a transient depression of sinus node automaticity followed by a junctional escape rhythm, with a ventricular rate of 66 beats/min that lasted 40 seconds.
The two nonresponders were converted to sinus rhythm by direct-current cardioversion.
Paroxysmal Atrial Fibrillation
The results in 12 patients with atrial fibrillation given diltiazem are listed in table 2. The amplitude of the fibrillatory waves was not diminished after diltiazem. Two patients (17%) converted to sinus rhythm, while the ventricular response was slowed to -100 beats/ min in eight patients after an average of 10.8 + 9 minutes after effective doses. Diltiazem acted rapidly; five patients reached the end point in 8 minutes or less.
The mean ventricular rate for the group decreased to 67% of the control value (p < 0.01) within 5 minutes of i.v. diltiazem and it increased slightly, to 73% of the control value (p < 0.05), after 30 minutes. In two patients, the R-R interval became more regular.
Two patients, one with an acute myocardial infarc-tion, reverted to sinus rhythm after diltiazem. Six patients required electrical cardioversion. The other four patients who had a history of multiple episodes of atrial fibrillation were treated with digitalis.
Paroxysmal Atrial Flutter Table 3 is a summary of results of treatment in the 12 patients who presented with paroxysmal atrial flutter. Before diltiazem was given, the rhythm was atrial flutter with 2:1 conduction in all cases. Six patients responded with an increase in AV block that resulted in a reduction in ventricular rate to 100 beats/min or less. In three patients, atrial flutter changed to atrial fibrillation with a "slow" ventricular response. The last three patients showed no appreciable change of the basic rhythm. Thus, the overall success rate was 75%. The mean time to the end point was 6.2 + 5. 1 minutes; five patients reached the end point within 5 minutes of diltiazem administration. Measurement of the FF intervals revealed no change in the flutter rate in any patient.
One of the patients in whom flutter changed to atrial fibrillation converted to sinus rhythm 2 hours after i.v. diltiazem. Patient 1 developed high-degree AV block 5 hours after diltiazem and required a temporary pacemaker. This patient was later diagnosed as having sick sinus syndrome. Eight patients underwent electrical cardioversion and two were treated with digitalis.
Side Effects
Intravenous diltiazem produced a transient but significant decrease in blood pressure from control, from 123 + 23/81 ± 16 mmHg to 99 ± 18/68 + 10mm Hg (p < 0.001). A less marked decrease, from 89 + 4/66 ± 5 to 83 + 6/61 ± 7 mm Hg (NS), was noted in seven patients whose control systolic blood pressure was low before treatment (< 100 mm Hg); none experienced symptoms after diltiazem administration. Only patients 8 and 9, who had presented supraventricular tachycardia, developed symptomatic hypotension. Both rapidly responded to Trendelenburg position and fluid administration. In both cases, the low single-dose schedule was used.
The patient with atrial flutter who developed highdegree AV block 5 hours after diltiazem was found to have sick sinus syndrome.
Intravenous diltiazem was safe in the seven patients who had heart failure and was also well tolerated by the patient who had an acute myocardial infarction. No serious postconversion ventricular arrhythmias were recorded in the 16 patients who received a direct-current countershock to restore sinus activity. There were no complications in the patients treated with digitalis before entry into the study. Countershock was applied 4.6 + 14.5 hours after i.v. diltiazem.
Discussion
Among the slow-channel calcium-blocking drugs available, diltiazem has emerged as a valuable agent for the therapy of variant angina.2-26 Although its role in other forms of angina has been studied,27 29the com-89 Abbreviations: MI = myocardial infarction; ACBG aortocoronary bypass graft; HTA systemic hypertension; DZ diltiazem; C control; HR = heart rate; BP = blood pressure: SR sinus rhythm. 1.5 5
1.5 11.5 (2) plete spectrum of therapeutic use of diltiazem remains unsettled. Few studies have evaluated the antiarrhythmic potential of this compound in the clinical situation.22' 23, 30 Electrophysiologic properties of diltiazem include a depressant effect on the rate of sinus node discharge as well as on conduction velocity through the AV node.22'23 Prolongation of AV nodal refractoriness and slowing of conduction by diltiazem provides the rationale for its clinical use in supraventricular tachyarrhythmias. Diltiazem has no significant inotropic effect. Given in equimolar doses to conscious dogs, verapamil and diltiazem produce equal changes in heart rate and aortic pressure. However, verapamil, but not diltiazem, decreased left ventricular performance.3'
Testing the efficacy and safety of a new antiarrhythmic drug can be difficult, since the dose schedule must be determined. We have shown in humans that the i.v. infusion of 15 gg/kg/min of diltiazem for 10 minutes, a dose reported to prolong the AV nodal refractory period,22 did not induce measurable systemic hemodynamic effects.2' Thus, we chose to start with a dose of 150 ,/g/kg, given as a bolus injection, to reach an early peak blood concentration. Although the decrease in blood pressure produced by the bolus injection may account for enhanced AV nodal conduction through a reflex baroreceptor response and increased catecholamine secretion, failure to achieve end points in some patients was thought to be due mainly to low blood levels of diltiazem. Consequently, a second injection was scheduled for nonresponders 30 minutes after the first injection. The three patients who received a repeat dose of 150 gg/kg did not reach an end point; therefore, the remaining patients were given 300 ,g/kg. Once tolerance of the higher dose was confirmed to shorten the time to the end point without significant side effects, a single injection of 300 ,ug/kg was given over 2 minutes as the initial bolus therapy.
Paroxysmal Supraventricular Tachycardia
Our data indicate that diltiazem is highly effective in the treatment of paroxysmal supraventricular tachycardia. Although one could argue that spontaneous return to sinus rhythm is characteristic of this type of arrhythmia, the rapid conversion to sinus rhythm within minutes after a bolus injection is strongly suggestive of drug efficacy. Spontaneous cessation of the two episodes that showed "late conversion" (13 minutes in patient 8 and 11 1/2minutes in patient 19) appears unlikely; tachycardia initiated 16 and 8 hours, respectively, before drug administration. Diltiazem was more effective than /3-adrenergic blocking agents, which are effective in only 50-60% of cases32 and which have a negative inotropic action. The high rate of arrhythmia conversion and rapidity of action are advantages of diltiazem over digitalis. The therapeutic value of diltiazem in paroxysmal supraventricular tachycardia appears to be comparable to that of verapamil, a drug reported to be effective in 76-100% of patients presenting with this arrhythmia.4-9 '4 Most cases of paroxysmal supraventricular tachycardia are due to AV nodal reentry, which could explain the effectiveness of both verapamil and diltiazem in controlling the ar- ' Values in parentheses indicate time to end point after effective dose. Abbreviations: MR = mitral regurgitation; LHF = left heart failure; CHF = congestive heart failure; Ao aortic; CP = constrictive pericarditis; M = mitral; ASD = atrial septal defect; ACBG = aortocoronary bypass graft; MS = mitral stenosis; DZ = diltiazem; HR heart rate; C = control; AF = atrial fibrillation; BP = blood pressure; SSS = sick sinus syndrome; SR = sinus rhythm. rhythmia. Because the present investigation was carried out in the emergency room, electrophysiologic studies were not performed. Hence, the underlying mechanism of tachycardia in the two nonresponders remains speculative. They may have had atrial or junctional ectopic tachycardia. Diltiazem in a concentration somewhat higher than that capable of blocking the slow inward current also inhibits the fast inward current and reduces the rate of rise of action potential. 19 Thus, larger doses of the drug might well suppress ectopic atrial or junctional tachycardias. Further analysis under carefuly controlled conditions is required, however, to validate this assumption.
Paroxysmal Atrial Fibrillation
Diltiazem was useful for the treatment of atrial fibrillation. A prompt decrease in the ventricular response was observed in eight patients and conversion to sinus rhythm in two (17%), yielding a success rate of 83%. Once again, these results are comparable to those reported for verapamil. Composite results from series of patients presenting with atrial fibrillation and treated with verapamil indicated that only 7% of patients reverted to sinus rhythm, whereas slowing of the ventricular rate occurred in 90%.2.s.6, 33 The latter value is similar to that in the present study. Even the two patients who failed to attain the target ventricular rate showed significant slowing of the ventricular response after diltiazem administration. Although verapamil produces an initial slowing of the ventricular rate that begins to accelerate within 30 minutes of a bolus injection.' diltiazem controlled the ventricular response throughout the study.
Paroxysmal Atrial Flutter
Six of our patients in atrial flutter (50%) responded to diltiazem with an increase in AV block that resulted in a reduction in ventricular rate. In three patients (25%), atrial flutter changed to atrial fibrillation with a controlled ventricular response. The development of atrial fibrillation has also been reported in 18% of patients receiving verapamil for atrial flutter, although the mechanism is not clear.2 5 3 Our patients with atrial flutter did not convert to sinus rhythm.
Side Effects
Intravenous diltiazem at the doses administered in this study appears to be safe. Dizziness, headaches and 92 CIRCULATION flushing, reported to occur in a few patients with longterm oral administration,34 were not observed in the present series, but a transient and mild fall in blood pressure was common. The only two episodes of symptomatic hypotension occurred in patients with no underlying heart disease who presented with supraventricular tachycardia. The rapid response to fluid administration suggests that an afterload mismatch due to peripheral vasodilation is the mechanism of the decreased blood pressure rather than decreased ventricular contractility, although a transient depression of myocardial contractility could not be ruled out. On the other hand, lack of negative inotropic activity of diltiazem explains why the drug was well tolerated by the seven patients in heart failure. No hemodynamic deterioration was observed in the patient presenting with an acute myocardial infarction, whereas slowing of the rapid heart rate was accompanied by relief of chest pain. The AV block with slow ventricular response in the patient with sick sinus syndrome occurred 5 SUMMARY To evaluate the influence of oral verapamil (80 and 120 mg) on angina threshold, coronary blood flow, myocardial oxygen consumption and left ventricular function, we subjected 13 patients with effort angina and fixed obstructive coronary artery disease to atrial pacing at progressively higher heart rates. After 120 mg of verapamil, the time to onset of angina and the heart rate at the onset of ST-segment depression increased by 18% (p < 0.005) and 10% (p < 0.001), respectively, without any change in the angina threshold (rate-pressure product at the onset of angina). The rate-pressure product, coronary blood flow and myocardial oxygen consumption were lower at rest and at pre-angina heart rates but not when the angina threshold was reached. Thus, the beneficial effect of verapamil was primarily due to decreased myocardial oxygen demand rather than to increased coronary blood flow. The decreased demand resulted from a lower arterial pressure at each pacing rate. In these patients without heart failure, left ventricular pump function did not deteriorate. This beneficial response was less with 80 mg of oral verapamil. These findings suggest that oral verapamil has a potential role in the management of patients with effort angina due to fixed obstructive coronary artery disease.
VERAPAMIL is effective in the treatment of vasospastic angina.' Because of its potential to decrease myocardial oxygen demand as well as to increase coronary blood flow,2-5 its use has also been advocated for the management of stable angina in patients with fixed obstructive coronary artery disease. Although clinical benefit from long-term oral verapamil therapy has been reported,3'the mechanisms for relief of angina after oral therapy in these patients have not been elucidated. In this study we determined the influence of oral verapamil on coronary and systemic hemodynamics, myocardial metabolism and angina threshold during atrial pacing in patients with fixed obstructive coronary artery disease.
Materials and Methods
Thirteen patients (seven males and six females) with stable angina that responded poorly to 13 blockers and nitrates were selected for the study. The patients were 48-81 years old and had had angina for 6 months to 8 years. Five patients had a remote myocardial infarction. In all patients, the coronary anatomy was known from selective coronary arteriograms. Significant obstructive lesions (D 50% stenosis) involving the left anterior descending, left circumflex, and right coronary arteries were present in six patients, left anterior descending and left circumflex arteries in three, and the left anterior descending and right coronary arteries in three. One patient had a lesion of the left anterior descending artery only. Twelve of the 13 patients were taking propranolol (160-320 mg) and all were taking nitrates (isosorbide dinitrate [Isordil] , 80-400 mg/ day). Propranolol was discontinued 5 days and nitrates 12 hours before the study. Each patient gave informed, written consent. The right side of the heart was catheterized with a flow-94 CIRCULATION
